NEC Corporation revealed the analysis outcome from efforts through AI prediction platforms that can design blueprints for SARS-CoV-2 vaccines in order to urge T-cell responses in major parts of the world population. This action by the scientific teams within the NEC Group to help fight COVID-19 outbreaks and support international vaccine development efforts is led by NEC OncoImmunity (NOI) in collaboration with NEC Laboratories Europe (NLE). These AI prediction platforms are supported by the AI technology used by NEC and NOI in the development of personalized neoantigen cancer vaccines.
During the analysis (published at bioRxiv), the team examined many sequences from the SARS-CoV-2 virus (the main cause of COVID-19) and detected epitopes (potential vaccine targets) for the 100 most common HLA alleles (diverse immunological makeup) in the world population. The prediction algorithms scanned for epitopes across the entire repertoire of proteins in SARS-CoV-2, not only the spike surface protein that gives this family of coronavirus its name. The team then used this data to identify “hotspots” in the viral proteome that contained overlapping and co-located epitopes from multiple HLA-alleles.
The optimal constellation of “hotspots” was then selected by their algorithms to generate the optimal immune response with the broadest coverage of the human population, whilst prioritizing hotspots that occurred in conserved regions of the viral proteome. These conserved regions are less likely to mutate in future strains. In addition, hotspots containing viral epitopes that had significant similarity with human proteins, especially those expressed in critical organs, were removed from the vaccine design blueprints to avoid adverse effects.
The analysis illustrates the paramount abilities of the NEC Group of leveraging their AI platforms to design blueprints for a vaccine that is efficacious and safe in a global population and could deal with the present and future divergent strains of the SARS-CoV-2 virus.
NEC Corporation is now publishing this research to encourage scientific advancements in the field. Also, it is ready to begin its efforts in partnerships to support the development of an effective vaccine targeting the world population.
“We are pleased that NEC’s AI technology can contribute to the resolution of serious problems facing the world today. As a company that seeks to enhance the well-being of society, NEC will continue to capitalize on research and development that maximizes the strengths of our AI technology to help prevent the spread of COVID-19. In collaboration with companies and institutions around the world, we aim to enable people to live their daily lives with as much safety and security as possible,” said Motoo Nishihara, Executive Vice President and Chief Technology Officer at NEC.
NEC OncoImmunity AS
“It has been exhilarating hard work between our CEO, Dr. Richard Stratford, the entire team at NEC OncoImmunity and our colleagues in the NEC Group to adapt our NEC Immune Profiler technology from its current cancer focus and quickly make it applicable to infectious diseases to help deal with the COVID-19 threat. It is encouraging that our AI and bioinformatics platform can design vaccine blueprints that have the potential to induce a broad immune response, that may not only be protective for the global population, but also stimulate a long-lived memory immune responses against SARS-CoV-2 and its future mutated versions,” said Dr. Trevor Clancy, Chief Scientific Officer at NEC OncoImmunity and the lead corresponding author in the paper.
NEC Laboratories Europe GmbH
“We have been repurposing our algorithms originally designed for predicting immune responses in individual cancer patients to scale to large population targets for infectious diseases. The in-silico validation of our algorithms takes into account the genetic background of humans across all continents. Now demonstrating that our predictions can contribute to the worldwide efforts to stop COVID-19 is of utmost importance. We have already started discussions with partner organizations for wet-lab validation activities. This is an important step towards the development of an effective vaccine for the global population,” said Dr. Saverio Niccolini, General Manager of the Data Science and System Platform Division at NEC Laboratories Europe GmbH.